A Recombinant Immunotoxin Against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-12-0336
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)


Related search